Westchester, Ill. – A study in the April 15 issue of the Journal of Clinical Sleep Medicine determined that over-the-counter melatonin medication can shorten the length of time it takes for children with autistic spectrum disorder (ASD), Fragile X Syndrome (FXS), or both to fall asleep at the beginning of the night.
Results indicate that children who received over-the-counter melatonin treatments experienced significant improvements in total night sleep durations, sleep latency times, and sleep-onset times. Mean sleep duration was longer on melatonin than placebo by 21 minutes, sleep-onset latency was shorter by 28 minutes and sleep-onset time was earlier by 42 minutes.
According to the senior author, Beth L. Goodlin-Jones, PhD of the M.I.N.D Institute at the University of California Davis Health System in Sacramento, Calif., treatment with over-the-counter melatonin supplements benefits children of all ages, which helps alleviate some of the additional stress that parents of special-needs children experience.
“Sleep onset problems at the beginning of the night are very troublesome for children and their families,” said Goodlin-Jones. “Sometimes children may take one to two hours to fall asleep and often they disrupt the household during this time.”
Authors indicate that sleep problems are reported in up to 89 percent of children with autism and 77 percent of children with FXS, the most common form of inherited mental impairment ranging from learning problems to mental retardation, and also the most commonly known cause of autism. Dyssomnia (difficulty falling asleep and frequent nighttime awakenings) is among the most commonly reported problems. Researchers hypothesize that difficulty sleeping in these children is increased due to abnormal levels of melatonin, a natural hormone secreted from the pineal gland that is believed to promote sleep at night.
The study gathered information from 12 children between the ages of 2 to 15.25 years. Sleep quality and quantity were measured both objectively and subjectively. Five participants met diagnostic criteria for autism, 3 for FXS, 3 for FXS and ASD, and 1 for FXS alone.
Participants were given a two-week supply of either melatonin or a placebo. After they completed the two-week dosage they were then crossed over to the alternate treatment for an additional two weeks. All participants were assessed for autism and received DNA testing for the diagnosis of FXS.
Authors recommend that in addition to the use of over-the-counter melatonin supplements, behavior therapies and sleep hygiene practices should be used to manage sleep problems in children with autism and FXS.
The Journal of Clinical Sleep Medicine (JCSM) contains published papers related to the clinical practice of sleep medicine, including original manuscripts such as clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the JCSM publishes proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine
For a copy of the study, “The Efficacy of Melatonin for Sleep Problems in Children with Autism, Fragile X Syndrome, or Autism and Fragile X Syndrome,” or to arrange an interview with an AASM spokesperson, please contact Kelly Wagner, AASM public relations coordinator, at (708) 492-0930, ext. 9331, or email@example.com
AASM is a professional membership organization dedicated to the advancement of sleep medicine and sleep-related research. As the national accrediting body for sleep disorders centers and laboratories for sleep related breathing disorders, the AASM promotes the highest standards of patient care. The organization serves its members and advances the field of sleep health care by setting the clinical standards for the field of sleep medicine, advocating for recognition, diagnosis and treatment of sleep disorders, educating professionals dedicated to providing optimal sleep health care and fostering the development and application of scientific knowledge.